IL‐6 inhibitors have been shown to be protective in patients with COVID‐19 (Liu et al., 2020; Zhang et al., 2020) and it has been proposed that IL‐6 inhibitors may also be protective during severe influenza infection (Hays et al., 2022). The gene discussed is IL6; the disease is COVID-19.